Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
575 articles about Emergent BioSolutions
-
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
9/26/2008
-
Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range
9/12/2008
-
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody
9/4/2008
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2008
8/7/2008
-
Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008
8/5/2008
-
Emergent BioSolutions Submits Proposal in Response to Department of Health and Human Services RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
8/1/2008
-
Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
7/30/2008
-
Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008
7/25/2008
-
Emergent BioSolutions Wins Grants Worth $4.5M
7/24/2008
-
Emergent BioSolutions and the University of Oxford form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust Sanger Institute and Aeras Global TB Vaccine Foundation
7/23/2008
-
Protein Sciences Responds to Emergent BioSolutions Lawsuit
7/11/2008
-
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and its Senior Management Regarding Delayed Asset Acquisition
7/10/2008
-
Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism
6/6/2008
-
Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
6/5/2008
-
Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008
6/4/2008
-
Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology
5/27/2008
-
Emergent BioSolutions Reports Financial Results for First Quarter 2008
5/7/2008
-
VaxGen, Inc. Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions
5/5/2008
-
Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008
4/10/2008
-
Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern
4/9/2008